Top-Rated StocksTop-RatedNASDAQ:MAZE Maze Therapeutics (MAZE) Stock Price, News & Analysis $25.66 -0.10 (-0.37%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Maze Therapeutics Stock (NASDAQ:MAZE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Maze Therapeutics alerts:Sign Up Key Stats Today's Range$25.49▼$26.0950-Day Range$24.46▼$51.8352-Week Range$9.73▼$53.65Volume180,797 shsAverage Volume712,454 shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$66.00Consensus RatingBuy Company Overview Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic. Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas. By integrating large‐scale genetic datasets with functional genomics assays, the company seeks to uncover previously unrecognized pathways that can be modulated by small molecules or biologics. Its target selection strategy is designed to deliver higher confidence in clinical proof‐of‐concept studies, and Maze’s research collaborations with academic and industry partners support the advancement of its most promising candidates through preclinical and early clinical stages. Headquartered in South San Francisco, California, Maze Therapeutics operates within a vibrant biotech cluster and draws on a network of scientific advisors and strategic collaborators worldwide. The company is led by a management team with extensive experience in genomics, drug development and translational research. By focusing on genetically validated targets and a disciplined go-to-clinic approach, Maze aims to bring transformative therapies to patients in need while creating value for its shareholders.AI Generated. May Contain Errors. Read More Maze Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreMAZE MarketRank™: Maze Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 628th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingMaze Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMaze Therapeutics has a consensus price target of $66.00, representing about 157.8% upside from its current price of $25.61.Amount of Analyst CoverageMaze Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Maze Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Maze Therapeutics are expected to decrease in the coming year, from ($2.65) to ($3.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maze Therapeutics is -10.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maze Therapeutics is -10.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaze Therapeutics has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.23% of the float of Maze Therapeutics has been sold short.Short Interest Ratio / Days to CoverMaze Therapeutics has a short interest ratio ("days to cover") of 5.64.Change versus previous monthShort interest in Maze Therapeutics has recently increased by 14.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaze Therapeutics does not currently pay a dividend.Dividend GrowthMaze Therapeutics does not have a long track record of dividend growth. News and Social Media0.9 / 5News Sentiment-0.60 News SentimentMaze Therapeutics has a news sentiment score of -0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Maze Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for MAZE on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Maze Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Maze Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,399,463.00 in company stock.Percentage Held by Insiders5.30% of the stock of Maze Therapeutics is held by insiders.Percentage Held by InstitutionsMaze Therapeutics has minimal institutional ownership at this time.Read more about Maze Therapeutics' insider trading history. Receive MAZE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maze Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAZE Stock News HeadlinesInsider Selling: Maze Therapeutics (NASDAQ:MAZE) CEO Sells 1,938 Shares of StockMay 19 at 5:07 AM | insidertrades.comMaze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in SharesMay 17, 2026 | fool.comMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction trading strategy for the first time. Since launching it, he's tracked 274 opportunities to double money fast across his services. Past trades include turning $5,000 into $10,000 on LMND in 6 minutes, $11,500 on QBTS in 2 hours, and $11,600 from META in 18 minutes. His next 'Fast Cash' trade posts before Monday.May 22 at 1:00 AM | Monument Traders Alliance (Ad)LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)May 17, 2026 | theglobeandmail.comIndustry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue ForecastsMay 17, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Maze Therapeutics, Inc. (MAZE)May 14, 2026 | theglobeandmail.comA Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price WeaknessMay 12, 2026 | finance.yahoo.comAtul Dandekar Sells 7,500 Shares of Maze Therapeutics (NASDAQ:MAZE) StockMay 2, 2026 | insidertrades.comSee More Headlines MAZE Stock Analysis - Frequently Asked Questions How have MAZE shares performed this year? Maze Therapeutics' stock was trading at $41.43 at the beginning of the year. Since then, MAZE shares have decreased by 38.2% and is now trading at $25.6060. How were Maze Therapeutics' earnings last quarter? Maze Therapeutics, Inc. (NASDAQ:MAZE) posted its earnings results on Tuesday, May, 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.02. The firm earned $20 million during the quarter. When did Maze Therapeutics IPO? Maze Therapeutics (MAZE) raised $140 million in an IPO on Friday, January 31st 2025. The company issued 8,750,000 shares at $15.00-$17.00 per share. Who are Maze Therapeutics' major shareholders? Top institutional shareholders of Maze Therapeutics include Janus Henderson Group PLC (5.17%), Candriam S.C.A. (0.56%), Spruce Street Capital LP (0.40%) and Bank of America Corp DE (0.35%). Insiders that own company stock include Jason V Coloma, Harold Bernstein, Amy Bachrodt, Atul Dandekar and Richard H Scheller. View institutional ownership trends. How do I buy shares of Maze Therapeutics? Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2026Today5/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MAZE's financial health is in the Yellow zone, according to TradeSmith. MAZE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MAZE Previous SymbolNASDAQ:MAZE CIK1842295 WebN/A Phone(650) 850-5070FaxN/AEmployees121Year Founded2018Price Target and Rating Average Price Target for Maze Therapeutics$66.00 High Price Target$110.00 Low Price Target$46.00 Potential Upside/Downside+156.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$131.12 million Net MarginsN/A Pretax Margin-612.71% Return on Equity-36.62% Return on Assets-31.78% Debt Debt-to-Equity Ratio0.11 Current Ratio17.88 Quick Ratio17.88 Sales & Book Value Annual Sales$167.50 million Price / Sales8.49 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book4.17Miscellaneous Outstanding Shares55,350,000Free Float52,412,000Market Cap$1.42 billion OptionableN/A Beta2.50 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MAZE) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne filing just changed the SpaceX IPO foreverSpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the larges...Behind the Markets | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
